<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">OR</journal-id>
<journal-title-group>
<journal-title>Oncology Reports</journal-title></journal-title-group>
<issn pub-type="ppub">1021-335X</issn>
<issn pub-type="epub">1791-2431</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name></publisher></journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/or.2013.2494</article-id>
<article-id pub-id-type="publisher-id">or-30-02-0856</article-id>
<article-categories>
<subj-group>
<subject>Articles</subject></subj-group></article-categories>
<title-group>
<article-title>Methylene blue-mediated photodynamic therapy enhances apoptosis in lung cancer cells</article-title></title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>LIM</surname><given-names>EUN JIN</given-names></name><xref rid="af1-or-30-02-0856" ref-type="aff">1</xref><xref rid="fn1-or-30-02-0856" ref-type="author-notes">&#x0002A;</xref></contrib>
<contrib contrib-type="author">
<name><surname>OAK</surname><given-names>CHUL-HO</given-names></name><xref rid="af2-or-30-02-0856" ref-type="aff">2</xref><xref rid="af4-or-30-02-0856" ref-type="aff">4</xref><xref rid="fn1-or-30-02-0856" ref-type="author-notes">&#x0002A;</xref></contrib>
<contrib contrib-type="author">
<name><surname>HEO</surname><given-names>JEONGHOON</given-names></name><xref rid="af1-or-30-02-0856" ref-type="aff">1</xref><xref rid="af3-or-30-02-0856" ref-type="aff">3</xref></contrib>
<contrib contrib-type="author">
<name><surname>KIM</surname><given-names>YOUNG-HO</given-names></name><xref rid="af1-or-30-02-0856" ref-type="aff">1</xref><xref rid="af3-or-30-02-0856" ref-type="aff">3</xref><xref rid="af4-or-30-02-0856" ref-type="aff">4</xref><xref ref-type="corresp" rid="c1-or-30-02-0856"/></contrib></contrib-group>
<aff id="af1-or-30-02-0856">
<label>1</label>Department of Molecular Biology and Immunology, Kosin University College of Medicine, Busan, Republic of Korea</aff>
<aff id="af2-or-30-02-0856">
<label>2</label>Department of Internal Medicine, Kosin University College of Medicine, Busan, Republic of Korea</aff>
<aff id="af3-or-30-02-0856">
<label>3</label>Institute for Medical Sciences, Kosin University College of Medicine, Busan, Republic of Korea</aff>
<aff id="af4-or-30-02-0856">
<label>4</label>Institute for International Healthcare Cooperation, Kosin University College of Medicine, Busan, Republic of Korea</aff>
<author-notes>
<corresp id="c1-or-30-02-0856">Correspondence to: Dr Young-Ho Kim, Department of Molecular Biology and Immunology, Kosin University College of Medicine, 34 Amnam-dong, Seo-gu, Busan 602-703, Republic of Korea, E-mail: <email>kimyh@kosin.ac.kr</email></corresp><fn id="fn1-or-30-02-0856">
<label>&#x0002A;</label>
<p>Contributed equally</p></fn></author-notes>
<pub-date pub-type="ppub">
<month>8</month>
<year>2013</year></pub-date>
<pub-date pub-type="epub">
<day>24</day>
<month>05</month>
<year>2013</year></pub-date>
<volume>30</volume>
<issue>2</issue>
<fpage>856</fpage>
<lpage>862</lpage>
<history>
<date date-type="received">
<day>07</day>
<month>02</month>
<year>2013</year></date>
<date date-type="accepted">
<day>25</day>
<month>04</month>
<year>2013</year></date></history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2013, Spandidos Publications</copyright-statement>
<copyright-year>2013</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0">
<license-p>This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.</license-p></license></permissions>
<abstract>
<p>Combined treatment with a photosensitizer and iodide laser &#x0005B;photodynamic therapy (PDT)&#x0005D; has improved the outcome of various cancers. In this study, we investigated the effects of using the photosensitizer methylene blue (MB) in PDT in human lung adenocarcinoma cells. We found that MB enhances PDT-induced apoptosis in association with downregulation of anti-apoptotic proteins, reduced mitochondrial membrane potential (MMP), increased phosphorylation of the mitogen-activated protein kinase (MAPK) and the generation of reactive oxygen species (ROS). In MB-PDT-treated A549 cells, we observed PARP cleavage, procaspase-3 activation, downregulation of the anti-apoptotic proteins Bcl-2 and Mcl-1, and the reduction of mitochondrial membrane potential (MMP). Western blot data showed that phosphorylation of p38 was increased in MB-PDT-treated A549 cells, indicating that several signaling molecules participate in the apoptotic cascade. Our data also showed that apoptotic cell death in MB-PDT-treated cells occurred through a series of steps beginning with the photochemical generation of ROS. Demonstrating the role of ROS, pretreatment of A549 cells with the antioxidant N-acetylcysteine (NAC) followed by MB-PDT resulted in increased cell viability and reduced proteolytic cleavage of PARP.</p></abstract>
<kwd-group>
<kwd>methylene blue</kwd>
<kwd>photodynamic therapy</kwd>
<kwd>apoptosis</kwd>
<kwd>lung</kwd></kwd-group></article-meta></front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Photodynamic therapy (PDT) is an emerging treatment for a variety of cancers and other diseases. In PDT the activation of a photosensitizer by a specific wavelength of light in the presence of oxygen promotes cellular damage (<xref rid="b1-or-30-02-0856" ref-type="bibr">1</xref>,<xref rid="b2-or-30-02-0856" ref-type="bibr">2</xref>). Currently, several research groups are developing PDT technology. A variety of photosensitizers such as Photofrin<sup>&#x000AE;</sup>, ALA and cisplatin have shown promising results (<xref rid="b1-or-30-02-0856" ref-type="bibr">1</xref>&#x02013;<xref rid="b3-or-30-02-0856" ref-type="bibr">3</xref>). However, improvements in quantum efficiency, reductions in toxicity and the ability to specifically target a highly effective dose have not been fully attained with current PDT technologies.</p>
<p>Methylene blue (MB), a well-known dye with high light absorption at 665 nm, is effective in PDT due to its ability to generate singlet oxygen and its proven photodynamic activity in clinical applications against several diseases (<xref rid="b4-or-30-02-0856" ref-type="bibr">4</xref>&#x02013;<xref rid="b6-or-30-02-0856" ref-type="bibr">6</xref>). Previous studies have documented the effectiveness of MB-PDT against melanoma in cell culture, and MB-PDT has been used to efficiently treat relatively large melanoma lesions not eligible for surgery (<xref rid="b6-or-30-02-0856" ref-type="bibr">6</xref>). In addition, some researchers have reported that MB is more toxic to leukemia cells than to normal PBMCs (<xref rid="b7-or-30-02-0856" ref-type="bibr">7</xref>). This suggests that MB is more toxic in cancer cells than normal cells, a potential benefit in reducing unwanted toxicity due to PDT.</p>
<p>Although it has been documented that in MB-PDT the derivative of MB induces apoptosis in several cell lines (<xref rid="b8-or-30-02-0856" ref-type="bibr">8</xref>), the current understanding of the mechanisms of apoptosis induced by MB-PDT is limited. Currently recognized mechanisms of apoptosis associated with MB-PDT include the induction of DNA damage, the generation of reactive oxygen species (ROS), and possibly mitochondrial damage (<xref rid="b9-or-30-02-0856" ref-type="bibr">9</xref>,<xref rid="b10-or-30-02-0856" ref-type="bibr">10</xref>). Published data have indicated mitochondrial damage in MB-PDT-induced tumor regression because MB is likely to bind to the negative electrochemical environment of the mitochondrial matrix in melanoma and HeLa cells (<xref rid="b11-or-30-02-0856" ref-type="bibr">11</xref>&#x02013;<xref rid="b13-or-30-02-0856" ref-type="bibr">13</xref>). A better understanding of the mechanisms of apoptosis induced by MB-PDT will help inform cancer therapeutic strategies.</p>
<p>In this study, we investigated the role of MB in PDT-induced apoptosis in human lung adenocarcinoma cells. We found that MB sensitizes A549 cells to PDT-induced apoptosis, suggesting that MB-PDT may provide an effective therapeutic strategy for lung adenocarcinoma. In addition, we found that caspase activation, downregulation of anti-apoptotic proteins, reduced mitochondrial membrane potential (MMP), activation of the mitogen-activated protein kinase (MAPK) p38, and ROS generation critically contribute to the anticancer effect of MB-PDT.</p></sec>
<sec sec-type="methods">
<title>Materials and methods</title>
<sec>
<title>Reagents</title>
<p>The methylene blue (MB) used for PDT was acquired from Aldrich (Milwaukee, WI, USA), and RPMI-1640 medium was purchased from Hyclone (Logan, UT, USA). Antibodies against PARP-1, Bcl-2, Bcl-xL, Mcl-1, and actin were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA), and anti-phospho-JNK, anti-phospho-p38, and anti-phospho-ERK were purchased from Cell Signaling (Beverly, MA, USA). Benzyl carbonyl-Val-Ala-Asp-fluoromethyl ketone (z-VAD-fmk) was purchased from Biomol (Plymouth Meeting, PA, USA), 2&#x02032;7&#x02032;-dichlorodihydrofluorescein diacetate (H<sub>2</sub>DCFDA) was purchased from Molecular Probes (Eugene, OR, USA), and N-acetylcysteine (NAC) and all other chemicals used in this study were purchased from Sigma-Aldrich (St. Louis, MO, USA).</p></sec>
<sec>
<title>Cell culture and chemical treatments</title>
<p>Human lung adenocarcinoma cells (A549 cells) were obtained from the American Type Culture Collection (Rockville, MD, USA). The A549 cells were cultured in RPMI-1640 medium supplemented with 10&#x00025; heat-inactivated fetal bovine serum (FBS), penicillin (100 U/ml) and streptomycin (100 U/ml) at 37&#x000BA;C in a humidified incubator with 5&#x00025; CO<sub>2</sub> and 95&#x00025; air. When the cells were subconfluent, the medium was replaced with fresh medium and 0.1&#x02013;2.0 &#x003BC;g/ml of MB was added to the culture medium for 1 h. The cells were then irradiated with 650 nm light produced by a dye laser (Red Diode Laser) at 30&#x02013;120 Joules (J).</p></sec>
<sec>
<title>Cellular viability assay</title>
<p>For the morphological evaluation of cell death, approximately 5&#x000D7;10<sup>5</sup> A549 cells were plated into 60-mm cell culture dishes overnight. For the trypan blue exclusion assay, trypsinized cells were pelleted and resuspended in 0.2 ml of medium, 0.5 ml of 0.4&#x00025; trypan blue solution, and 0.3 ml of phosphate-buffered saline solution (PBS). The samples were mixed thoroughly, incubated at room temperature for 15 min, and examined under a light microscope. At least 300 cells were counted for each survival determination.</p></sec>
<sec>
<title>Western blot analysis</title>
<p>For western blot analyses, A549 cells were lysed with 1X Laemmli lysis buffer (2.4 M glycerol, 0.14 M Tris, pH 6.8, 0.21 M SDS, 0.3 mM bromophenol blue) and boiled for 10 min. Protein content was measured with the BCA Protein Assay Reagent (Pierce, Rockford, IL, USA). The samples were diluted with 1X Laemmli lysis buffer containing 1.28 M &#x003B2;-mercaptoethanol, and equal amounts of protein were loaded on 8&#x02013;12&#x00025; SDS-polyacrylamide gels. Proteins were separated by SDS-PAGE and electrophoretically transferred to a nitrocellulose membrane. The nitrocellulose membrane was blocked with 5&#x00025; nonfat dry milk in PBS-Tween-20 (0.1&#x00025;, v/v) for 1 h. The membrane was incubated with primary antibody (diluted according to the manufacturer&apos;s instructions) at room temperature for 1.5 h. Horseradish peroxidase-conjugated anti-rabbit or anti-mouse IgG was used as the secondary antibody. Immunoreactive protein was visualized by the chemiluminescence protocol (ECL, Amersham, Arlington Heights, IL, USA). To ensure equal protein loading, each nitrocellulose membrane was stripped and reprobed with an anti-actin antibody after the experiment was completed.</p></sec>
<sec>
<title>DNA fragmentation and DAPI staining assay</title>
<p>To assess for DNA fragmentation after MB and/or PDT for 24 h, ~1&#x000D7;10<sup>6</sup> treated A549 cells were lysed for 30 min on ice in buffer containing 10 mM Tris (pH 7.4), 150 mM NaCl, 5 mM EDTA and 0.5&#x00025; Triton X-100. Lysates were vortexed and cleared by centrifugation at 12,000 &#x000D7; g for 30 min. Fragmented DNA in the supernatant was extracted with an equal volume of a mixture of neutral phenol:chloroform:isoamyl alcohol (25:24:1) and analyzed electrophoretically on 1.5&#x00025; agarose gels containing 0.1 g/ml EtBr. The cells were fixed on slide glass through the application of 4&#x00025; paraformaldehyde for 30 min at room temperature. After washing with PBS, 300 nM 4&#x02032;, 6&#x02032;-diamidino-2-phenylindole (DAPI) was added to the fixed cells for 10 min, after which they were examined by fluorescence microscopy. Apoptotic cells were identified by condensation and fragmentation of nuclei. All DAPI staining experiments were performed in duplicate.</p></sec>
<sec>
<title>Measurement of reactive oxygen species</title>
<p>The generation of ROS was measured by staining with 2&#x02032;,7&#x02032;-dichlorofluorescein diacetate (DCF-DA). Briefly, A549 cells were seeded in six-well plates (1&#x000D7;10<sup>5</sup> cells per well), allowed to attach overnight and treated with MB and/or PDT. The cells were stained with 20 &#x003BC;M DCF-DA for 30 min at 37&#x000BA;C and fluorescence was detected by a fluorescence microscope.</p></sec>
<sec>
<title>JC-1 mitochondrial membrane potential assay</title>
<p>To monitor MMP, JC-1 dye was used as previously described (<xref rid="b14-or-30-02-0856" ref-type="bibr">14</xref>). In cells with undamaged mitochondria, the aggregated dye appears as red fluorescence, whereas in cells with altered MMP that are undergoing apoptosis, the dye remains as monomers in the cytoplasm and emits diffuse green fluorescence. The red/green fluorescence ratio is dependent on MMP. After A549 cells were treated with MB and PDT, they were stained with a JC-1 MMP detection kit for 10 min and analyzed by flow cytometry. The fluorescence intensity was measured with the FACScan flow cytometer (Beckman Coulter, Inc., Hialeah, FL, USA).</p></sec>
<sec>
<title>Statistical analysis</title>
<p>All experiments were repeated three or more times. The results are represented as means &#x000B1; standard deviations (SDs). The difference between two mean values was analyzed using Student&apos;s t-test and was considered statistically significant at p&lt;0.05.</p></sec></sec>
<sec sec-type="results">
<title>Results</title>
<sec>
<title>Methylene blue promotes PDT-mediated A549 cell toxicity</title>
<p>To evaluate the effects of MB-PDT on cell viability, A549 cells were treated with various concentrations of MB and/or PDT (30 and 60 J) for 24 h and a trypan blue assay was performed. As shown in <xref rid="f1-or-30-02-0856" ref-type="fig">Fig. 1</xref>, while MB alone had little effect on cell viability, MB treatment followed by PDT significantly decreased cell viability as determined by trypan blue exclusion (<xref rid="f1-or-30-02-0856" ref-type="fig">Fig. 1A</xref>) and DAPI staining (<xref rid="f1-or-30-02-0856" ref-type="fig">Fig. 1B</xref>). These results suggest that PDT enhances the toxicity of MB in A549 cells.</p></sec>
<sec>
<title>Methylene blue promotes PDT-induced apoptosis by caspase activation</title>
<p>To address the significance of caspase activation in MB-PDT-induced apoptosis, we examined caspase activity after MB-PDT. Treatment of A549 cells with various concentrations of MB and PDT resulted in a dramatic increase in the cleavage of PARP, a caspase substrate, and in the cleavage of procaspase-3 (<xref rid="f2-or-30-02-0856" ref-type="fig">Fig. 2A</xref>) in a time-dependent manner (<xref rid="f2-or-30-02-0856" ref-type="fig">Fig. 2B</xref>). In order to confirm that the activation of caspases is a key step in MB-PDT-induced apoptosis, the A549 cells were pretreated with z-VAD-fmk (25 &#x003BC;M), a cell-permeable caspase inhibitor, followed by MB-PDT for 24 h. As shown in <xref rid="f2-or-30-02-0856" ref-type="fig">Fig. 2C</xref>, MB-PDT-induced apoptosis was prevented by pretreatment with z-VAD-fmk, as indicated by the reduced PARP cleavage. We also found that z-VAD-fmk prevented the dose-dependent increase in the accumulation of apoptotic DNA after treatment with MB-PDT (<xref rid="f2-or-30-02-0856" ref-type="fig">Fig. 2D</xref>). These results suggest that MB-PDT-induced cell death is associated with caspase activation.</p></sec>
<sec>
<title>MB and PDT induce downregulation of anti-apoptotic proteins and loss of mitochondrial membrane potential in A549 cells</title>
<p>We further examined whether MB-PDT-induced apoptosis is associated with the modulation of apoptosis regulatory proteins. As shown in <xref rid="f3-or-30-02-0856" ref-type="fig">Fig. 3A</xref>, exposure of A549 cells to MB and PDT led to a slight decrease in Bcl-xL. However, levels of Bcl-2 and Mcl-1 in A549 cells were markedly reduced by MB and PDT in a dose-dependent manner. We assessed MMP in order to determine the role of mitochondrial damage in MB-PDT-induced apoptosis of A549 cells. As shown in <xref rid="f3-or-30-02-0856" ref-type="fig">Fig. 3B</xref>, we found that exposure of A549 cells to MB and PDT significantly reduced MMP in a dose-dependent manner. The proportion of cells with a loss of MMP substantially increased with MB treatment (1 and 2 &#x003BC;g/ml) plus PDT (60 J).</p></sec>
<sec>
<title>Activation of p38 signaling plays an important role in MB-induced photosensitization in A549 cells</title>
<p>In order to investigate whether a MAPK signaling pathway was involved in cell death in A549 cells treated with MB-PDT, we examined the phosphorylation of p38, JNK and ERK in A549 cells after MB and/or PDT. As shown in <xref rid="f4-or-30-02-0856" ref-type="fig">Fig. 4A</xref>, p38 activity was increased slightly at 2 h after MB application (2 &#x003BC;g/ml) and the increased p38 activity was sustained after 8 h of treatment with MB alone, whereas a much stronger and prolonged activation of p38 was observed after combined treatment with MB and PDT. To further confirm the involvement of the p38 signaling pathway in MB-PDT-induced apoptosis, we applied specific inhibitors of JNK (SP600125), p38 (SB203589), and ERK (PD98059). Pretreatment of A549 cells with the p38 inhibitor SB203589 before MB-PDT increased cell viability (<xref rid="f4-or-30-02-0856" ref-type="fig">Fig. 4B</xref>) and reduced proteolytic cleavage of PARP (<xref rid="f4-or-30-02-0856" ref-type="fig">Fig. 4C</xref>). Taken together, these results suggest that the prolonged activation of the MAPK p38 pathway plays an important role in MB-induced photosensitization.</p></sec>
<sec>
<title>MB potentiates PDT-induced ROS generation, which is attenuated by the addition of antioxidants to A549 cells</title>
<p>ROS are byproducts of the normal metabolism of oxygen, and they are generated by various environmental stresses such as drugs, UV light and heat shock. ROS play an important role in apoptosis under both physiologic and pathologic conditions (<xref rid="b15-or-30-02-0856" ref-type="bibr">15</xref>,<xref rid="b16-or-30-02-0856" ref-type="bibr">16</xref>). Therefore, we examined whether ROS generation was involved in MB-induced photosensitization of A549 cells by measuring the intracellular hydrogen peroxide level in A549 cells after MB-PDT. As shown in <xref rid="f5-or-30-02-0856" ref-type="fig">Fig. 5A</xref>, the combination of MB and PDT markedly increased intracellular hydrogen peroxide levels in A549 cells. We next investigated whether ROS generation was directly associated with MB-PDT-induced apoptosis. Pretreatment with NAC, a well-known antioxidant, markedly increased cell viability after MB-PDT (<xref rid="f5-or-30-02-0856" ref-type="fig">Fig. 5B</xref>). Moreover, apoptosis induced by MB-PDT was markedly attenuated by pretreatment with NAC (<xref rid="f5-or-30-02-0856" ref-type="fig">Fig. 5C</xref>). Taken together, these results indicate that MB-induced photosensitization and MB-PDT-induced apoptosis are mediated by the generation of ROS.</p></sec></sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>Although PDT is a commonly applied cancer therapy, its efficacy is limited by injury to healthy tissue, varying tumor sensitivity and various other side effects. Therefore, novel therapeutic strategies are needed to selectively induce the death of cancer cells while sparing normal cells. Recently, many attempts to improve the therapeutic effects of PDT have been reported (<xref rid="b17-or-30-02-0856" ref-type="bibr">17</xref>) and several photosensitizers such as porfimer sodium (Photofrin), ALA and cisplatin have been used to enhance tumor cell death in PDT (<xref rid="b18-or-30-02-0856" ref-type="bibr">18</xref>,<xref rid="b19-or-30-02-0856" ref-type="bibr">19</xref>). In this study, we found that MB effectively sensitizes A549 human lung adenocarcinoma cells to PDT-induced apoptosis through caspase activation, downregulation of anti-apoptotic proteins, reduced MMP, activation of p38 signaling pathways and increased ROS.</p>
<p>MB is already approved for systemic administration by intravenous injection for clinical use in patients with other diseases. It has various biological applications, it is used as a staining dye for parathyroid tissue (<xref rid="b20-or-30-02-0856" ref-type="bibr">20</xref>), an antifungal agent in goldfish, and an antimalarial agent (<xref rid="b21-or-30-02-0856" ref-type="bibr">21</xref>). In the present study, we showed that compared with MB or PDT alone, the combination of MB and PDT resulted in significantly enhanced A549 cell death (<xref rid="f1-or-30-02-0856" ref-type="fig">Fig. 1</xref>). This enhancement of PDT-induced apoptosis by MB was dependent on caspase activation, since z-VAD-fmk, a caspase inhibitor, reduced the cell death induced by MB-PDT (<xref rid="f2-or-30-02-0856" ref-type="fig">Fig. 2</xref>).</p>
<p>Mitochondria play an important role in apoptotic pathways that result from a variety of intracellular events including the release of caspase activators, changes in MMP, ROS generation, and changes in the Bcl-2 family of proteins (<xref rid="b22-or-30-02-0856" ref-type="bibr">22</xref>). In the current study, loss of MMP was observed in A549 cells co-treated with MB and PDT (<xref rid="f3-or-30-02-0856" ref-type="fig">Fig. 3</xref>). Levels of Bcl-2 in A549 cells were also markedly decreased by MB-PDT. Taken together, these results suggest that the mitochondrial pathway is involved in the enhancement of PDT-induced apoptosis by MB.</p>
<p>The activation of MAPK pathways plays an essential role in apoptosis induced by many cellular stresses. The p38 MAPK is activated by ROS in many cells treated with radiation, anticancer drugs, and chemopreventive agents (<xref rid="b23-or-30-02-0856" ref-type="bibr">23</xref>). In our study, MB-PDT-treated A549 cells showed remarkably activated p38, but not JNK or ERK MAPK (<xref rid="f4-or-30-02-0856" ref-type="fig">Fig. 4</xref>). Pretreatment of A549 cells with the p38 inhibitor SB203589 prevented MB-PDT-induced apoptosis. These results suggest that activation of the p38 MAPK pathway contributes to MB-PDT-induced apoptosis in A549 cells.</p>
<p>ROS are generated by many environmental stresses (e.g., UV light and heat shock), and they are produced as a normal product of cellular metabolism (e.g., phagocytosis). ROS play an important role in apoptosis induction under both physiologic and pathologic conditions (<xref rid="b16-or-30-02-0856" ref-type="bibr">16</xref>). In the current study, we show that co-treatment with MB and PDT induced ROS generation in A549 cells. Furthermore, antioxidant (NAC) pretreatment attenuated ROS generation and MB-PDT-induced apoptosis (<xref rid="f4-or-30-02-0856" ref-type="fig">Fig. 4</xref>), suggesting that the elevation of ROS levels by combined treatment with MB and PDT plays an important role in enhancing the apoptotic susceptibility of A549 cells.</p>
<p>In conclusion, the present study shows that MB enhances PDT-induced apoptosis in human lung adenocarcinoma cells via caspase activation, reductions in anti-apoptotic protein levels, loss of MMP, activation of the p38 MAPK signaling pathway and ROS generation. Therefore, a combined regimen of MB and PDT may offer a better therapeutic strategy to enhance photosensitivity in tumor cells.</p></sec></body>
<back>
<ack>
<title>Acknowledgements</title>
<p>This work was supported by Basic Science Research Program through the NRF funded by the Ministry of Education, Science and Technology (2011-0004206) and a grant from Kosin University College of Medicine (2011) and a grant from Institute for Medical Sciences (2011).</p></ack>
<ref-list>
<title>References</title>
<ref id="b1-or-30-02-0856"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dougherty</surname><given-names>TJ</given-names></name><name><surname>Gomer</surname><given-names>CJ</given-names></name><name><surname>Henderson</surname><given-names>BW</given-names></name><name><surname>Jori</surname><given-names>G</given-names></name><name><surname>Kessel</surname><given-names>D</given-names></name><name><surname>Korbelik</surname><given-names>M</given-names></name><name><surname>Moan</surname><given-names>J</given-names></name><name><surname>Peng</surname><given-names>Q</given-names></name></person-group><article-title>Photodynamic therapy</article-title><source>J Natl Cancer Inst</source><volume>90</volume><fpage>889</fpage><lpage>905</lpage><year>1998</year></element-citation></ref>
<ref id="b2-or-30-02-0856"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dolmans</surname><given-names>DE</given-names></name><name><surname>Fukumura</surname><given-names>D</given-names></name><name><surname>Jain</surname><given-names>RK</given-names></name></person-group><article-title>Photodynamic therapy for cancer</article-title><source>Nat Rev Cancer</source><volume>3</volume><fpage>380</fpage><lpage>387</lpage><year>2003</year></element-citation></ref>
<ref id="b3-or-30-02-0856"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharman</surname><given-names>WM</given-names></name><name><surname>Allen</surname><given-names>CM</given-names></name><name><surname>van Lier</surname><given-names>JE</given-names></name></person-group><article-title>Photodynamic therapeutics: basic principles and clinical applications</article-title><source>Drug Discov Today</source><volume>4</volume><fpage>507</fpage><lpage>517</lpage><year>1999</year></element-citation></ref>
<ref id="b4-or-30-02-0856"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bisland</surname><given-names>SK</given-names></name><name><surname>Chien</surname><given-names>C</given-names></name><name><surname>Wilson</surname><given-names>BC</given-names></name><name><surname>Burch</surname><given-names>S</given-names></name></person-group><article-title>Pre-clinical in vitro and in vivo studies to examine the potential use of photodynamic therapy in the treatment of osteomyelitis</article-title><source>Photochem Photobiol Sci</source><volume>5</volume><fpage>31</fpage><lpage>38</lpage><year>2006</year></element-citation></ref>
<ref id="b5-or-30-02-0856"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tardivo</surname><given-names>JP</given-names></name><name><surname>Del Giglio</surname><given-names>A</given-names></name><name><surname>Paschoal</surname><given-names>LH</given-names></name><name><surname>Baptista</surname><given-names>MS</given-names></name></person-group><article-title>New photodynamic therapy protocol to treat AIDS-related Kaposi&apos;s sarcoma</article-title><source>Photomed Laser Surg</source><volume>24</volume><fpage>528</fpage><lpage>531</lpage><year>2006</year></element-citation></ref>
<ref id="b6-or-30-02-0856"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>M</given-names></name><name><surname>Suarez</surname><given-names>ER</given-names></name><name><surname>Theodoro</surname><given-names>TR</given-names></name><name><surname>Machado Filho</surname><given-names>CD</given-names></name><name><surname>Gama</surname><given-names>MF</given-names></name><name><surname>Tardivo</surname><given-names>JP</given-names></name><name><surname>Paschoal</surname><given-names>FM</given-names></name><name><surname>Pinhal</surname><given-names>MA</given-names></name></person-group><article-title>Methylene blue photodynamic therapy in malignant melanoma decreases expression of proliferating cell nuclear antigen and heparanases</article-title><source>Clin Exp Dermatol</source><volume>37</volume><fpage>527</fpage><lpage>533</lpage><year>2012</year></element-citation></ref>
<ref id="b7-or-30-02-0856"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirszberg</surname><given-names>C</given-names></name><name><surname>Rumjanek</surname><given-names>VM</given-names></name><name><surname>Capella</surname><given-names>MA</given-names></name></person-group><article-title>Methylene blue is more toxic to erythroleukemic cells than to normal peripheral blood mononuclear cells: a possible use in chemotherapy</article-title><source>Cancer Chemother Pharmacol</source><volume>56</volume><fpage>659</fpage><lpage>665</lpage><year>2005</year></element-citation></ref>
<ref id="b8-or-30-02-0856"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ball</surname><given-names>DJ</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Kessel</surname><given-names>D</given-names></name><name><surname>Griffiths</surname><given-names>J</given-names></name><name><surname>Brown</surname><given-names>SB</given-names></name><name><surname>Vernon</surname><given-names>DI</given-names></name></person-group><article-title>The induction of apoptosis by a positively charged methylene blue derivative</article-title><source>J Photochem Photobiol B</source><volume>42</volume><fpage>159</fpage><lpage>163</lpage><year>1998</year></element-citation></ref>
<ref id="b9-or-30-02-0856"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noodt</surname><given-names>BB</given-names></name><name><surname>Rodal</surname><given-names>GH</given-names></name><name><surname>Wainwright</surname><given-names>M</given-names></name><name><surname>Peng</surname><given-names>Q</given-names></name><name><surname>Horobin</surname><given-names>R</given-names></name><name><surname>Nesland</surname><given-names>JM</given-names></name><name><surname>Berg</surname><given-names>K</given-names></name></person-group><article-title>Apoptosis induction by different pathways with methylene blue derivative and light from mitochondrial sites in V79 cells</article-title><source>Int J Cancer</source><volume>75</volume><fpage>941</fpage><lpage>948</lpage><year>1988</year></element-citation></ref>
<ref id="b10-or-30-02-0856"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodrigues</surname><given-names>T</given-names></name><name><surname>de Fran&#x000E7;a</surname><given-names>LP</given-names></name><name><surname>Kawai</surname><given-names>C</given-names></name><name><surname>de Faria</surname><given-names>PA</given-names></name><name><surname>Mugnol</surname><given-names>KC</given-names></name><name><surname>Braga</surname><given-names>FM</given-names></name><name><surname>Tersariol</surname><given-names>IL</given-names></name><name><surname>Smaili</surname><given-names>SS</given-names></name><name><surname>Nantes</surname><given-names>IL</given-names></name></person-group><article-title>Protective role of mitochondrial unsaturated lipids on the preservation of the apoptotic ability of cytochrome C exposed to singlet oxygen</article-title><source>J Biol Chem</source><volume>282</volume><fpage>25577</fpage><lpage>25587</lpage><year>2007</year></element-citation></ref>
<ref id="b11-or-30-02-0856"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gabrielli</surname><given-names>D</given-names></name><name><surname>Belisle</surname><given-names>E</given-names></name><name><surname>Severino</surname><given-names>D</given-names></name><name><surname>Kowaltowski</surname><given-names>AJ</given-names></name><name><surname>Baptista</surname><given-names>MS</given-names></name></person-group><article-title>Binding, aggregation and photochemical properties of methylene blue in mitochondrial suspensions</article-title><source>Photochem Photobiol</source><volume>79</volume><fpage>227</fpage><lpage>232</lpage><year>2004</year></element-citation></ref>
<ref id="b12-or-30-02-0856"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Zhong</surname><given-names>J</given-names></name><name><surname>Ji</surname><given-names>J</given-names></name><name><surname>Shen</surname><given-names>P</given-names></name></person-group><article-title>Apoptosis induced by methylene-blue-mediated photodynamic therapy in melanomas and the involvement of mitochondrial dysfunction revealed by proteomics</article-title><source>Cancer Sci</source><volume>99</volume><fpage>2019</fpage><lpage>2027</lpage><year>2008</year></element-citation></ref>
<ref id="b13-or-30-02-0856"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Jiao</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Zhong</surname><given-names>J</given-names></name><name><surname>Ji</surname><given-names>J</given-names></name><name><surname>Shen</surname><given-names>P</given-names></name></person-group><article-title>Methylene blue-mediated photodynamic therapy induces mitochondria-dependent apoptosis in HeLa cell</article-title><source>J Cell Biochem</source><volume>105</volume><fpage>1451</fpage><lpage>1460</lpage><year>2008</year></element-citation></ref>
<ref id="b14-or-30-02-0856"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>MJ</given-names></name><name><surname>Lee</surname><given-names>TH</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Choi</surname><given-names>YJ</given-names></name><name><surname>Heo</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>YH</given-names></name></person-group><article-title>Triptolide inactivates Akt and induces caspase-dependent death in cervical cancer cells via the mitochondrial pathway</article-title><source>Int J Oncol</source><volume>37</volume><fpage>1177</fpage><lpage>1185</lpage><year>2010</year></element-citation></ref>
<ref id="b15-or-30-02-0856"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szatrowski</surname><given-names>TP</given-names></name><name><surname>Nathan</surname><given-names>CF</given-names></name></person-group><article-title>Production of large amounts of hydrogen peroxide by human tumor cells</article-title><source>Cancer Res</source><volume>51</volume><fpage>794</fpage><lpage>798</lpage><year>1991</year></element-citation></ref>
<ref id="b16-or-30-02-0856"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simon</surname><given-names>HU</given-names></name><name><surname>Haj-Yehia</surname><given-names>A</given-names></name><name><surname>Levi-Schaffer</surname><given-names>F</given-names></name></person-group><article-title>Role of reactive oxygen species (ROS) in apoptosis induction</article-title><source>Apoptosis</source><volume>5</volume><fpage>415</fpage><lpage>418</lpage><year>2000</year></element-citation></ref>
<ref id="b17-or-30-02-0856"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Firczuk</surname><given-names>M</given-names></name><name><surname>Winiarska</surname><given-names>M</given-names></name><name><surname>Szokalska</surname><given-names>A</given-names></name><name><surname>Jodlowska</surname><given-names>M</given-names></name><name><surname>Swiech</surname><given-names>M</given-names></name><name><surname>Bojarczuk</surname><given-names>K</given-names></name><name><surname>Salwa</surname><given-names>P</given-names></name><name><surname>Nowis</surname><given-names>D</given-names></name></person-group><article-title>Approaches to improve photodynamic therapy of cancer</article-title><source>Front Biosci</source><volume>16</volume><fpage>208</fpage><lpage>224</lpage><year>2011</year></element-citation></ref>
<ref id="b18-or-30-02-0856"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nahabedian</surname><given-names>MY</given-names></name><name><surname>Cohen</surname><given-names>RA</given-names></name><name><surname>Contino</surname><given-names>MF</given-names></name><name><surname>Terem</surname><given-names>TM</given-names></name><name><surname>Wright</surname><given-names>WH</given-names></name><name><surname>Berns</surname><given-names>MW</given-names></name><name><surname>Wile</surname><given-names>AG</given-names></name></person-group><article-title>Combination cytotoxic chemotherapy with cisplatin or doxorubicin and photodynamic therapy in murine tumors</article-title><source>J Natl Cancer Inst</source><volume>80</volume><fpage>739</fpage><lpage>743</lpage><year>1988</year></element-citation></ref>
<ref id="b19-or-30-02-0856"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>Q</given-names></name><name><surname>Warloe</surname><given-names>T</given-names></name><name><surname>Moan</surname><given-names>J</given-names></name><name><surname>Godal</surname><given-names>A</given-names></name><name><surname>Apricena</surname><given-names>F</given-names></name><name><surname>Giercksky</surname><given-names>KE</given-names></name><name><surname>Nesland</surname><given-names>JM</given-names></name></person-group><article-title>Antitumor effect of 5-aminolevulinic acid-mediated photodynamic therapy can be enhanced by the use of a low dose of photofrin in human tumor xenografts</article-title><source>Cancer Res</source><volume>61</volume><fpage>5824</fpage><lpage>5832</lpage><year>2001</year></element-citation></ref>
<ref id="b20-or-30-02-0856"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sherlock</surname><given-names>DJ</given-names></name><name><surname>Holl-Allen</surname><given-names>RT</given-names></name></person-group><article-title>Intravital methylene blue staining of parathyroid glands and tumours</article-title><source>Ann R Coll Surg Engl</source><volume>66</volume><fpage>396</fpage><lpage>398</lpage><year>1984</year></element-citation></ref>
<ref id="b21-or-30-02-0856"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meissner</surname><given-names>PE</given-names></name><name><surname>Mandi</surname><given-names>G</given-names></name><name><surname>Coulibaly</surname><given-names>B</given-names></name><name><surname>Witte</surname><given-names>S</given-names></name><name><surname>Tapsoba</surname><given-names>T</given-names></name><name><surname>Mansmann</surname><given-names>U</given-names></name><name><surname>Rengelshausen</surname><given-names>J</given-names></name><name><surname>Schiek</surname><given-names>W</given-names></name><name><surname>Jahn</surname><given-names>A</given-names></name><name><surname>Walter-Sack</surname><given-names>I</given-names></name><name><surname>Mikus</surname><given-names>G</given-names></name><name><surname>Burhenne</surname><given-names>J</given-names></name><name><surname>Riedel</surname><given-names>KD</given-names></name><name><surname>Schirmer</surname><given-names>RH</given-names></name><name><surname>Kouyat&#x000E9;</surname><given-names>B</given-names></name><name><surname>M&#x000FC;ller</surname><given-names>O</given-names></name></person-group><article-title>Methylene blue for malaria in Africa: results from a dose-finding study in combination with chloroquine</article-title><source>Malar J</source><volume>5</volume><fpage>84</fpage><year>2006</year></element-citation></ref>
<ref id="b22-or-30-02-0856"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>ES</given-names></name><name><surname>Choi</surname><given-names>MJ</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Choi</surname><given-names>KS</given-names></name><name><surname>Kwon</surname><given-names>TK</given-names></name></person-group><article-title>Combination of withaferin A and X-ray irradiation enhances apoptosis in U937 cells</article-title><source>Toxicol In Vitro</source><volume>25</volume><fpage>1803</fpage><lpage>1810</lpage><year>2011</year></element-citation></ref>
<ref id="b23-or-30-02-0856"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>YR</given-names></name><name><surname>Tan</surname><given-names>TH</given-names></name></person-group><article-title>The c-Jun N-terminal kinase pathway and apoptotic signaling</article-title><source>Int J Oncol</source><volume>16</volume><fpage>651</fpage><lpage>662</lpage><year>2000</year></element-citation></ref></ref-list></back>
<floats-group>
<fig id="f1-or-30-02-0856" position="float">
<label>Figure 1</label>
<caption>
<p>Cytotoxicity of MB and PDT in A549 cells. (A) A549 cells were treated with the indicated concentrations of MB followed by laser irradiation (30 and 60 J). A trypan blue assay was then used to measure cell viability. <sup>&#x0002A;</sup>p&lt;0.05 compared with MB-treated cells (B) A549 cells after DAPI staining. A549 cells were fixed, washed with PBS, stained with DAPI and examined by fluorescence microscopy. Data are expressed as the mean &#x000B1; SD of three independent experiments.</p></caption>
<graphic xlink:href="OR-30-02-0856-g00.gif"/></fig>
<fig id="f2-or-30-02-0856" position="float">
<label>Figure 2</label>
<caption>
<p>Effects of MB-PDT on caspase activation in A549 cells. (A) A549 cells were treated with the indicated concentrations of MB before PDT and incubated for 24 h. Equal amounts of cell lysates (20 &#x003BC;g) were subjected to electrophoresis and analyzed by western blotting for PARP, procaspase-3 and actin. (B) A549 cells were treated with MB (2 &#x003BC;g/ml) or PDT (60 J) or both for various time periods. Equal amounts of cell lysates (20 &#x003BC;g) were subjected to electrophoresis and analyzed by western blotting for PARP and actin. (C) A549 cells were pre-incubated with 25 &#x003BC;M z-VAD-fmk for 1 h before combined treatment with MB and PDT for 24 h. Equal amounts of cell lysates (20 &#x003BC;g) were subjected to electrophoresis and analyzed by western blotting for PARP and actin. (D) A549 cells were pre-incubated with 25 &#x003BC;M z-VAD-fmk for 1 h before combined treatment with MB and PDT for 24 h. Fragmented DNA was extracted and analyzed on a 2&#x00025; agarose gel.</p></caption>
<graphic xlink:href="OR-30-02-0856-g01.gif"/></fig>
<fig id="f3-or-30-02-0856" position="float">
<label>Figure 3</label>
<caption>
<p>Effects of MB and PDT on anti-apoptotic protein expression and mitochondrial function in A549 cells. (A) The levels of apoptosis-related protein expression was analyzed after treatment with MB and/or PDT in A549 cells. Equal amounts of whole cell lysate (20 &#x003BC;g) were subjected to electrophoresis and analyzed by western blotting for Bcl-2, Bcl-xL and Mcl-1. Western blotting of actin served as an internal control. (B) Loss of MMP following treatment with MB and/or PDT. A549 cells were treated with MB or PDT or both for 24 h, then incubated with JC-1 for 1 h. Fluorescence was measured by flow cytometry.</p></caption>
<graphic xlink:href="OR-30-02-0856-g02.gif"/></fig>
<fig id="f4-or-30-02-0856" position="float">
<label>Figure 4</label>
<caption>
<p>Effects of MB and PDT on the p38 MAPK signaling pathway. (A) A549 cells were treated with MB (2 &#x003BC;g/ml) and/or PDT (60J) for various time periods. Levels of phosphorylated p38, JNK and ERK were detected by western blotting using specific p-p38, p-JNK and p-ERK antibodies. (B) A549 cells were pretreated with specific inhibitors of JNK (SP600125), p38 (SB203589) and ERK (PD98059) at the indicated concentration and further treated with 2 &#x003BC;g/ml of MB and PDT for 24 h. Cell viability was then assessed by trypan blue assay. <sup>&#x0002A;</sup>p&lt;0.05 compared with MB&#x0002B;PDT treated cells (C) A549 cells were pretreated with SB203589 at the indicated concentration and further treated with 2 &#x003BC;g/ml of MB and PDT for 24 h. Equal amounts of whole cell lysates were subjected to electrophoresis and analyzed by western blotting for PARP, and actin served as a loading control.</p></caption>
<graphic xlink:href="OR-30-02-0856-g03.gif"/></fig>
<fig id="f5-or-30-02-0856" position="float">
<label>Figure 5</label>
<caption>
<p>Effects of MB and PDT on ROS generation in A549 cells. (A) A549 cells were pre-incubated in the absence or presence of MB (1 &#x003BC;g/ml) for 1 h and subsequently treated with or without a PDT (60 J) for 24 h. Cells were then incubated with 20 &#x003BC;M DCFDA at 37&#x000BA;C for 30 min and ROS generation was measured using a flow cytometer or a fluorescence microscope. (B) A549 cells were pre-incubated in the presence or absence of NAC (10 mM) for 1 h and subsequently treated with or without MB plus an iodide laser for 24 h. Cell viability was then assessed by a trypan blue assay. <sup>&#x0002A;</sup>p&lt;0.05 compared with MB&#x0002B;PDT-treated cells. (C) A549 cells were pre-incubated in the presence or absence of NAC (10 mM) and subsequently treated with MB (1 &#x003BC;g/ml) and a PDT (60 J) for 24 h. Equal amounts of whole cell lysates (20 &#x003BC;g) were subjected to electrophoresis and analyzed by western blotting for PARP, and actin served as a loading control.</p></caption>
<graphic xlink:href="OR-30-02-0856-g04.gif"/></fig></floats-group></article>
